Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

• Verfasst von: Patel, Manesh [VerfasserIn]
• Verfasst von: Mahaffey, Kenneth W. [VerfasserIn]
• Verfasst von: Garg, Jyotsna [VerfasserIn]
• Verfasst von: Pan, Guohua [VerfasserIn]
• Verfasst von: Singer, Daniel E. [VerfasserIn]
• Verfasst von: Hacke, Werner [VerfasserIn]
• Verfasst von: Breithardt, Günter [VerfasserIn]
• Verfasst von: Halperin, Jonathan L. [VerfasserIn]
• Verfasst von: Hankey, Graeme J. [VerfasserIn]
• Verfasst von: Piccini, Jonathan P. [VerfasserIn]
• Verfasst von: Becker, Richard C. [VerfasserIn]
• Verfasst von: Nessel, Christopher C. [VerfasserIn]
• Verfasst von: Paolini, John F. [VerfasserIn]
• Verfasst von: Berkowitz, Scott D. [VerfasserIn]
• Verfasst von: Fox, Keith A. A. [VerfasserIn]
• Verfasst von: Califf, Robert M. [VerfasserIn]
• Titel: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
• Verf.angabe: Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, M.S., Guohua Pan, Ph.D., Daniel E. Singer, M.D., Werner Hacke, M.D., Ph.D., Günter Breithardt, M.D., Jonathan L. Halperin, M.D., Graeme J. Hankey, M.D., Jonathan P. Piccini, M.D., Richard C. Becker, M.D., Christopher C. Nessel, M.D., John F. Paolini, M.D., Ph.D., Scott D. Berkowitz, M.D., Keith A.A. Fox, M.B., Ch.B., Robert M. Califf, M.D., and the ROCKET AF Steering Committee, for the ROCKET AF Investigators*
• Jahr: 2011
• Umfang: 9 S.
• Fussnoten: Gesehen am 18.11.2014
• Titel Quelle: Enthalten in: The New England journal of medicine
• Ort Quelle: Waltham, Mass. : MMS, 1928
• Jahr Quelle: 2011
• Band/Heft Quelle: 365(2011), 10, Seite 883-91
• ISSN Quelle: 1533-4406
• DOI: doi:10.1056/NEJMc1112233
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Administration, Oral
• Sach-SW: Aged
• Sach-SW: Aged, 80 and over
• Sach-SW: Anticoagulants
• Sach-SW: Atrial Fibrillation
• Sach-SW: Double-Blind Method
• Sach-SW: Embolism
• Sach-SW: Female
• Sach-SW: Hemorrhage
• Sach-SW: Humans
• Sach-SW: Intention to Treat Analysis
• Sach-SW: Male
• Sach-SW: Middle Aged
• Sach-SW: Morpholines
• Sach-SW: Rivaroxaban
• Sach-SW: Stroke
• Sach-SW: Thiophenes
• Sach-SW: Treatment Outcome
• Sach-SW: Warfarin
• K10plus-PPN: 1487149204

Abstract

BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin. - METHODS: In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin. The per-protocol, as-treated primary analysis was designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of stroke or systemic embolism. - RESULTS: In the primary analysis, the primary end point occurred in 188 patients in the rivaroxaban group (1.7% per year) and in 241 in the warfarin group (2.2% per year) (hazard ratio in the rivaroxaban group, 0.79; 95% confidence interval [CI], 0.66 to 0.96; P<0.001 for noninferiority). In the intention-to-treat analysis, the primary end point occurred in 269 patients in the rivaroxaban group (2.1% per year) and in 306 patients in the warfarin group (2.4% per year) (hazard ratio, 0.88; 95% CI, 0.74 to 1.03; P<0.001 for noninferiority; P=0.12 for superiority). Major and nonmajor clinically relevant bleeding occurred in 1475 patients in the rivaroxaban group (14.9% per year) and in 1449 in the warfarin group (14.5% per year) (hazard ratio, 1.03; 95% CI, 0.96 to 1.11; P=0.44), with significant reductions in intracranial hemorrhage (0.5% vs. 0.7%, P=0.02) and fatal bleeding (0.2% vs. 0.5%, P=0.003) in the rivaroxaban group. - CONCLUSIONS: In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.).